Using a pathway-centered approach, our work also identified molecular mechanisms, like EMT, a non-genetically driven known mechanism of resistance to anti-cancer compounds including EGFR inhibitors [51], uniquely attributable to subpopulations of cancer cells less responsive to treatment [52–54]. Here, EGFR is linked to cancer.